Oppenheimer analyst Jay Olson maintains $Enanta Pharmaceuticals (ENTA.US)$ with a hold rating, and adjusts the target price from $16 to $14.
According to TipRanks data, the analyst has a success rate of 37.6% and a total average return of 10.8% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Enanta Pharmaceuticals (ENTA.US)$'s main analysts recently are as follows:
Enanta reported Q4 results highlighting quarterly HCV royalties of $14.6M, operating expenses of $44.5M, and cash reserves of $248.2M, anticipated to sustain operations into 2027. The company is poised to announce topline results from its Phase 2 RSVPEDs study of zelicapavir in infants and children with RSV in December.
The firm noted that the Q4 report was straightforward and emphasized the critical nature of the upcoming RSVPEDs readout in December, which is expected to be a key determinant of zelicapavir's future potential in RSV.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
奥本海默控股分析师Jay Olson维持$Enanta Pharmaceuticals (ENTA.US)$持有评级，并将目标价从16美元下调至14美元。
根据TipRanks数据显示，该分析师近一年总胜率为37.6%，总平均回报率为10.8%。
此外，综合报道，$Enanta Pharmaceuticals (ENTA.US)$近期主要分析师观点如下：
Enanta公司发布了第四季度的业绩，突出了季度HCV特许权使用费为1460万美元，营业费用为4450万美元，以及现金储备为24820万美元，预计将维持运营到2027年。该公司计划在12月宣布其zelicapavir在感染RSV的婴儿和儿童中的第二阶段RSVPEDs研究的顶线结果。
该公司提到第四季度报告很简单明了，并强调即将到来的12月RSVPEDs结果的重要性，这被预计将是zelicapavir在RSV中未来潜力的关键决定因素。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
